| Prode P. Pascual, M.d., Inc. | |
|
18331 Gridley Rd Suite C Cerritos CA 90703-5438 | |
| (562) 865-0213 | |
| (562) 865-1050 |
| Full Name | Prode P. Pascual, M.d., Inc. |
|---|---|
| Speciality | Clinic/Center |
| Location | 18331 Gridley Rd, Cerritos, California |
| Authorized Official Name and Position | Prode Pascual (CEO) |
| Authorized Official Contact | 5628650213 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Prode P. Pascual, M.d., Inc. 18331 Gridley Rd Suite C Cerritos CA 90703-5438 Ph: (562) 865-0213 | Prode P. Pascual, M.d., Inc. 18331 Gridley Rd Suite C Cerritos CA 90703-5438 Ph: (562) 865-0213 |
| NPI Number | 1649646209 |
|---|---|
| Provider Enumeration Date | 08/18/2015 |
| Last Update Date | 08/18/2015 |
| Medicare PECOS PAC ID | 8224347232 |
|---|---|
| Medicare Enrollment ID | O20151014000620 |
News Archive
A new study published recently in ScienceDirect by researchers from Syracuse University and SUNY Upstate Medical University shows that people with intellectual and developmental disabilities living in residential group homes are more likely to be diagnosed with COVID-19 and die from the virus than those without IDD.
Mutation of a gene involved in non-small cell lung cancer (NSCLC) increases the likelihood that the drug gefitinib (Iressa™) will show a beneficial response, researchers at the Dana-Farber Cancer Institute, the National Cancer Institute (NCI) - part of the National Institutes of Health - and two other institutions announced today in the online version of Science.
BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that it will present its nanoparticle technology and the latter's advantages in therapeutic applications at the French-Norwegian Interdisciplinary Symposium on Nano and Micro Frontiers in Biology and Medicine, to take place in Bergen, Norway, from August 31 to September 2, 2009.
UCLA scientists have shown that temporarily blocking a protein critical to immune response actually helps the body clear itself of chronic infection. Published in the April 12 edition of Science, the finding suggests new approaches to treating persistent viral infections like HIV and hepatitis C.
The vision for the partnership is to incorporate artificial intelligence into online GP consultations by providing accessible information that is certified and verified by Health Commissions so that we reduce the demand for GP services. The underlying aim or objective is to shape demand for healthcare services.
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649646209 | NPI | - | NPPES |
| 00A309860 | Medicaid | CA | |
| A30986 | Other | MEDICARE ID-TYPE UNSPECIFIED |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QP2300X | Clinic/center - Primary Care | A30986 (California) | Primary |
| Provider Name | Prode P Pascual |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1558454595 PECOS PAC ID: 5890822720 Enrollment ID: I20100423000367 |
News Archive
A new study published recently in ScienceDirect by researchers from Syracuse University and SUNY Upstate Medical University shows that people with intellectual and developmental disabilities living in residential group homes are more likely to be diagnosed with COVID-19 and die from the virus than those without IDD.
Mutation of a gene involved in non-small cell lung cancer (NSCLC) increases the likelihood that the drug gefitinib (Iressa™) will show a beneficial response, researchers at the Dana-Farber Cancer Institute, the National Cancer Institute (NCI) - part of the National Institutes of Health - and two other institutions announced today in the online version of Science.
BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that it will present its nanoparticle technology and the latter's advantages in therapeutic applications at the French-Norwegian Interdisciplinary Symposium on Nano and Micro Frontiers in Biology and Medicine, to take place in Bergen, Norway, from August 31 to September 2, 2009.
UCLA scientists have shown that temporarily blocking a protein critical to immune response actually helps the body clear itself of chronic infection. Published in the April 12 edition of Science, the finding suggests new approaches to treating persistent viral infections like HIV and hepatitis C.
The vision for the partnership is to incorporate artificial intelligence into online GP consultations by providing accessible information that is certified and verified by Health Commissions so that we reduce the demand for GP services. The underlying aim or objective is to shape demand for healthcare services.
› Verified 9 days ago
| Provider Name | Allen Kris Navarro |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1679237598 PECOS PAC ID: 9830570894 Enrollment ID: I20220721002706 |
News Archive
A new study published recently in ScienceDirect by researchers from Syracuse University and SUNY Upstate Medical University shows that people with intellectual and developmental disabilities living in residential group homes are more likely to be diagnosed with COVID-19 and die from the virus than those without IDD.
Mutation of a gene involved in non-small cell lung cancer (NSCLC) increases the likelihood that the drug gefitinib (Iressa™) will show a beneficial response, researchers at the Dana-Farber Cancer Institute, the National Cancer Institute (NCI) - part of the National Institutes of Health - and two other institutions announced today in the online version of Science.
BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that it will present its nanoparticle technology and the latter's advantages in therapeutic applications at the French-Norwegian Interdisciplinary Symposium on Nano and Micro Frontiers in Biology and Medicine, to take place in Bergen, Norway, from August 31 to September 2, 2009.
UCLA scientists have shown that temporarily blocking a protein critical to immune response actually helps the body clear itself of chronic infection. Published in the April 12 edition of Science, the finding suggests new approaches to treating persistent viral infections like HIV and hepatitis C.
The vision for the partnership is to incorporate artificial intelligence into online GP consultations by providing accessible information that is certified and verified by Health Commissions so that we reduce the demand for GP services. The underlying aim or objective is to shape demand for healthcare services.
› Verified 9 days ago
News Archive
A new study published recently in ScienceDirect by researchers from Syracuse University and SUNY Upstate Medical University shows that people with intellectual and developmental disabilities living in residential group homes are more likely to be diagnosed with COVID-19 and die from the virus than those without IDD.
Mutation of a gene involved in non-small cell lung cancer (NSCLC) increases the likelihood that the drug gefitinib (Iressa™) will show a beneficial response, researchers at the Dana-Farber Cancer Institute, the National Cancer Institute (NCI) - part of the National Institutes of Health - and two other institutions announced today in the online version of Science.
BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that it will present its nanoparticle technology and the latter's advantages in therapeutic applications at the French-Norwegian Interdisciplinary Symposium on Nano and Micro Frontiers in Biology and Medicine, to take place in Bergen, Norway, from August 31 to September 2, 2009.
UCLA scientists have shown that temporarily blocking a protein critical to immune response actually helps the body clear itself of chronic infection. Published in the April 12 edition of Science, the finding suggests new approaches to treating persistent viral infections like HIV and hepatitis C.
The vision for the partnership is to incorporate artificial intelligence into online GP consultations by providing accessible information that is certified and verified by Health Commissions so that we reduce the demand for GP services. The underlying aim or objective is to shape demand for healthcare services.
› Verified 9 days ago
Sam Soleymani Apex Imaging Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 18003 Harvest Ave, Cerritos, CA 90703 Phone: 562-304-6566 Fax: 562-261-2939 | |
Hichang Choi, M.d., Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 12229 Artesia Blvd, Cerritos, CA 90703 Phone: 562-865-5121 Fax: 562-865-2321 | |
Caremore Health Medical Partners West, Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 12900 Park Plaza Dr Ste 150, Cerritos, CA 90703 Phone: 562-622-2800 | |
Integrative Diagnostic Group Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 12231 Artesia Blvd, Cerritos, CA 90703 Phone: 562-653-0180 Fax: 562-402-3029 | |
Rosemarie J. Melchor, Md, Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 10802 College Pl, Cerritos, CA 90703 Phone: 562-924-9500 | |
First Medical Center Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 11841 South St, Cerritos, CA 90703 Phone: 562-809-8082 Fax: 562-809-3893 | |
Knowble Health Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 12915 Berkhamsted St, Cerritos, CA 90703 Phone: 562-644-5459 |